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Purpose: To study the feasibility of unified intensity-modulated arc therapy (UIMAT) which com-
bines intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) opti-
mization and delivery to produce superior radiation treatment plans, both in terms of dose distribution
and efficiency of beam delivery when compared with either VMAT or IMRT alone.
Methods: An inverse planning algorithm for UIMAT was prototyped within the  treatment
planning system (Philips Healthcare). The IMRT and VMAT deliveries are unified within the same
arc, with IMRT being delivered at specific gantry angles within the arc. Optimized gantry angles
for the IMRT and VMAT phases are assigned automatically by the inverse optimization algorithm.
Optimization of the IMRT and VMAT phases is done simultaneously using a direct aperture opti-
mization algorithm. Five treatment plans each for prostate, head and neck, and lung were generated
using a unified optimization technique and compared with clinical IMRT or VMAT plans. Delivery
verification was performed with an ArcCheck phantom (Sun Nuclear) on a Varian TrueBeam linear
accelerator (Varian Medical Systems).
Results: In this prototype implementation, the UIMAT plans offered the same target dose coverage
while reducing mean doses to organs at risk by 8.4% for head-and-neck cases, 5.7% for lung cases,
and 3.5% for prostate cases, compared with the VMAT or IMRT plans. In addition, UIMAT can be
delivered with similar efficiency as VMAT.
Conclusions: In this proof-of-concept work, a novel radiation therapy optimization and deliv-
ery technique that interlaces VMAT or IMRT delivery within the same arc has been demon-
strated. Initial results show that unified VMAT/IMRT has the potential to be superior to
either standard IMRT or VMAT. C 2015 American Association of Physicists in Medicine.
[http://dx.doi.org/10.1118/1.4905373]
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1. INTRODUCTION
Volumetric-modulated arc therapy (VMAT) has been rapidly
adopted by the radiotherapy community due primarily to its
delivery speed and monitor unit (MU) efficiency, as well
as the quality of conformal dose distributions achievable.1–3
On the other hand, intensity-modulated radiotherapy (IMRT)
with its static beam directions might be advantageous in cases
where steep dose gradients or highly intensity-modulated
beam intensities are required in preferred directions.4 While
the community tends to regard these two delivery techniques
as disparate entities, they are in reality special cases of one
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another. More specifically, there exists a unifying delivery
technique which bridges the gap between static-gantry IMRT
and rotating-gantry VMAT. Such a unified delivery, if properly
implemented into an inverse-planning algorithm, would in
general lead to improved dose delivery capabilities as the
algorithm could naturally optimize the beam within a given
arc range to be more IMRT-like if greater beam intensity
modulation is required, or more VMAT-like if increased
conformity is required with less beam intensity modulation.
This combined approach would take advantage of the two
modes of beam delivery for targeting and normal tissue
sparing.
IMRT or VMAT delivery is typically represented by con-
trol points (CP)—or multileaf collimator (MLC) segments—
which are essentially snapshots of the positions of the relevant
linear accelerator components taken at regular intervals. For
example, a VMAT beam can be stored as a series of con-
trol points specifying the machine parameters at regular 2◦ or
4◦ intervals of the rotating gantry. Due to the large number
of degrees-of-freedom required to specify a VMAT beam,
all VMAT radiotherapy plans are created using specialized
optimization software, such as SmartArc in  (Philips
Healthcare, Fitchburg) or RapidArc in Eclipse (Varian Medical
Systems, Palo Alto). Both commercial treatment planning sys-
tems optimize beam parameters specifically for equally spaced
gantry positions. In addition to commercially available soft-
ware, a number of research prototypes have been developed
to test novel optimization algorithms including the concept of
unequally spaced control points.5,6 In principle, VMAT and
IMRT with and without gantry rotation, respectively, can be
unified during optimization and delivery. Instead of forcing the
beam angle increments for arc therapy, the fixed-gantry IMRT
parameters can add additional degrees of freedom available to
the optimization engine.
The idea to combine VMAT and IMRT deliveries is not new,
and various ideas have been proposed to improve the current
clinically available VMAT implementations. One suggestion,
termed dense angularly sampled and sparse intensity modu-
lated radiation therapy (DASSIM-RT), proposes a method
to search more thoroughly through the parameter space of
machine-deliverable radiotherapy plans.7 One major hurdle
toward the clinical implementation of this method is that the
scale of the optimization problem is now immense and so much
greater computer memory is required.8 Another proposal,
arc modulated radiation therapy (AMRT), builds on previous
work in intensity modulated arc therapy (IMAT).1 AMRT is
a sequencing algorithm that allows multiple IMAT arcs to be
delivered by a single arc. In one study, AMRT plans required
on the order of 200–400 segments and achieved similar plan
quality to IMRT.9
Yet another proposal, termed FusionArc, has recently been
published.10 This paper describes an in-house optimization
software that begins with a full VMAT optimization fol-
lowed by an iterative conversion, at select gantry angles,
from uniform to intensity-modulated fluence. Gantry angles
are selected for conversion based on a gradient function,
which attempts to predict conversions that will lead to the
greatest reduction in the cost function. Brainlab (Feldkirchen,
Germany) has introduced a commercial platform, which first
optimizes a dynamic conformal arc delivery phase followed
by an optimization of an IMRT phase. However, the arc phase
is restricted by constant angular speed and dose rate. Further-
more, the arc ranges, the number of uniformly spaced IMRT
fields, and the relative weighting of arc and fixed-gantry IMRT
phases must all be chosen from the outset of optimization.11
The quality of HybridArc plans has been shown to depend on
a proper selection of these initial parameters.12
None of the solutions described above has yet embodied
the fully integrated and unified approach that we advocate
here. The purpose of this work is to create, as a proof-of-
principle, a unified intensity-modulated arc therapy (UIMAT)
that combines IMRT and VMAT optimization and delivery
in order to produce efficient and superior radiation treatment
plans in a single optimization with concurrent VMAT and
IMRT features.
2. MATERIALS AND METHODS
2.A. Inverse planning for UIMAT
Custom software was developed and integrated into a
commercial treatment planning system,  (Ref. 3) v9.6
Radiation Therapy Planning Systems (Philips Healthcare,
Fitchburg) for the purpose of testing whether UIMAT is
superior to either standard VMAT or IMRT. This software
extends ’s built-in VMAT optimization in a few key
ways. First, it removes the restriction that control points
within a dynamic arc must have a uniform angular spacing.
Importantly, this allows arc segments that would benefit
from increased intensity modulation to have more densely
packed control points. Furthermore, angles requiring this
increased modulation are selected automatically during the
initial optimization stage, and this can be thought of as a form
of beam-angle optimization.
Our optimization algorithm begins by creating static beams
uniformly distributed between start and stop arc angles with
an initially coarse control point spacing of 24◦, as suggested
by Bzdusek.13 Using ’s inverse-planning system, an
optimized fluence pattern is determined for these initial
beams. In general, these fluence patterns will not be machine-
deliverable and so a sequencing step is then performed, which
converts the fluence patterns into executable MLC control
points.
Custom software is then initiated which reads in this beam
information from  software. As a preparatory step, the
code first reorders the control points within each individual
beam, anticipating that these control points may later be
distributed—or fanned out—into other gantry angles to form
an arc segment. The goals of this reordering step are (1)
to preferentially place higher-weighted control points toward
the middle of the order, thereby minimizing the dosimetric
differences between the original and the fanned out beams (see
Fig. 1); (2) to minimize MLC motion between control points,
thereby improving delivery efficiency. Note that for any given
solution, there will always be a “symmetric” solution having
the reverse control point order. However, this symmetry is
Medical Physics, Vol. 42, No. 2, February 2015
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F. 1. Schematic showing how the control points from the initial fixed-beam optimization are distributed into VMAT and IMRT phases. Control points within
each beam have been reordered to minimize MLC motion. As well, higher-weighted control points are preferentially placed in the middle of the ordering to
minimize the difference between the initial and final gantry angles. Interpolated MLC segments are inserted as necessary to maintain a maximum control point
spacing of four degrees.
broken once neighboring beams are considered, and so for
each beam the software determines whether the original or
reverse order will result in the least MLC motion between the
first and last control points of neighboring beams.
The algorithm next determines which of these beams
should remain as IMRT fields and which should be converted
into arc segments. In our current implementation, we chose
to convert those beams having fewer than four control points
(low modulation) into a “VMAT phase,” while those beams
with four or more control points were retained for the “IMRT
phase” (high modulation). In this study, the threshold to
distinguish between low and high modulation corresponds
approximately to the average number of control points
per beam, which in turn depends on the MLC sequencing
parameters chosen. Based on the parameters we chose, on
average, we had four control points per beam, which we
found to work well practically for the anatomical sites tested.
Finally, the algorithm modifies the gantry angle associated
with each beam segment as shown in Fig. 1. Beams that have
low modulation become VMAT phases where their control
points are distributed uniformly within the 24◦ spacing. In
order to maintain approximately four-degree spacing between
control points, linear interpolation of MLC leaves is used to
create new interlaced control points as needed. Beams that
have high modulation become IMRT phases. In this case, the
first and last control points have their gantry angles shifted
8◦ on either side of the initial gantry angle, as shown in Fig. 1.
These two boundary control points, together with linearly
interpolated control points, are used to facilitate a smooth
transition from VMAT to IMRT phases. Next, the central
control points of high-modulation beams are fanned out
around the initial gantry angle in 0.2◦ increments. Interpolated
control points are then added between these central control
points to arrive at a 0.1◦ spacing for the IMRT phase. The
small gantry rotation (almost stalled) for the IMRT phase
approximates a static-gantry IMRT field and is a work-around
for the fact that  v9.6 does not allow simultaneous
DMPO optimization of static-gantry IMRT and VMAT beams.
At this stage, the beam control points are reimported into
 for a final optimization using the DMPO algorithm.
As an example, the start and stop angles for these partial arcs,
as well as the angular location of the IMRT phases, are shown
in Fig. 2.
Certain “soft” deliverability constraints are relaxed for the
IMRT-like portions of delivery. Specifically, for the IMRT
phases, the maximum MU per degree is increased from 20
to 200, and the gantry acceleration limit is removed. Within
 software, this is accomplished by defining a separate
machine having these special properties and associating the
IMRT phases with this virtual machine. This is required in
order to have a reasonable number of MUs delivered during
the more highly modulated IMRT phase, which may have
up to ten control points within one degree angular spacing.
It is important to note that such a beam is still machine
F. 2. A typical UIMAT plan. The angular ranges for three VMAT phases
are represented by arc segments while the fixed gantry angles corresponding
to four IMRT phases are represented by straight line pairs.
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deliverable as it does not violate any physical constraints of
the accelerator.
From this point on, optimization proceeds using the stan-
dard functionality within . Machine parameters for
both IMRT phases and VMAT phases are optimized at the
same time as multiple dynamic arcs in  software.
DMPO optimization is continued until a clinically accept-
able plan is obtained using standard dose–volume histogram
(DVH) constraints. During optimization, the VMAT and IMRT
phases are treated as separate beams, and after optimization is
complete, our custom software is used to combine the VMAT
and IMRT phases into a single UIMAT arc with variable gantry
speed for final dose calculation and delivery. The final dose
is calculated by collapsed cone convolution algorithm in the
 treatment planning system.
2.B. Treatment plan evaluation
In order to test our optimization algorithm, CT scans
from 15 previously treated patients were selected for plann-
ing comparison purposes. Five cases each were randomly
selected from head-and-neck, lung, and prostate sites to
represent a variety of anatomy, complexity levels, and delivery
modalities. All clinical treatment plans were optimized using
the  treatment planning system. A summary of the
selected patient plans is provided in Table I with the estimated
delivery times obtained from . Since  does
not provide an estimate for step-and-shoot beams, the delivery
time for IMRT plans was measured on a Varian linear
accelerator. The IMRT delivery time is defined here as the
total time from when the first beam turns on until the last
beam turns off and so includes the “mode-up” time as well
as the time required to move to the various gantry positions.
Beams were ordered for the most efficient delivery. A paired,
two-tailed t-test was used to assess for statistically significant
differences in delivery times.
The UIMAT plans were optimized based on our local treat-
ment planning guidelines used to generate the clinical plans.
Without exception, critical structure tolerances such as the
spinal cord and brainstem were respected. For lung cases,
the volume of both lungs receiving at least 20 Gy (V20) was
kept below 35% and a mean lung dose of <20 Gy was also
maintained. The dose coverage goal for the planning target
volume (PTV) was to cover at least 95% of the PTV by at least
95% of the prescription dose. For noncritical structures, DVH
criteria from RTOG 0126 and QUANTEC (Ref. 14) were used
to guide the planning process. All UIMAT plans were restricted
to a single arc. Dynamic jaw movements were allowed in order
to facilitate the goal of a single-arc delivery. Dynamic jaws
were required when treating large volumes with a single arc
due to the finite speed and length of the MLC leaves. It is
noted that the clinical plans did not require dynamic jaws, as
all complicated VMAT plans standardly use two arcs.
To compare a UIMAT plan with the corresponding clinical
VMAT or IMRT plan for each patient, various dose metrics
were selected and subjected to a paired, one-tailed t-test to
assess statistically significant differences. Mean doses for
PTVs and conformity index (CI) were analyzed for all cases.
The conformity index has been previously defined as15
CI = cover factor×spill factor
=
(
V100(PTV)
VPTV
)
×
(
V100(PTV)
V100(body)
)
, (1)
where V100(PTV) and V100(body) are the volumes of the
100% prescription dose within the PTV and body, respec-
tively, and VPTV is the volume of the PTV. For head-and-neck
T I. Comparison of clinically delivered treatments with UIMAT treatment plans. Note that some patients had multiple target volumes with distinct dose
levels (e.g., Patient 3 had both a 70 Gy and a 56 Gy target volume). Approximate treatment delivery times are given.
Beam arrangement Delivery time (s)
Patient Site Dose pres. (Gy) Clinical UIMAT Clinical UIMAT
Head and neck 1 Lt. parotid 64/60/54 2 × 210◦ (108 CP) 1 × 210◦ (65 CP) 91 64
2 Rt. parotid 60 2 × 225◦ (116 CP) 1 × 225◦ (55 CP) 95 68
3 Larynx/neck 70/56 2 × 360◦ (182 CP) 1 × 360◦ (87 CP) 151 171
4 Parotids/neck 70/56 2 × 360◦ (182 CP) 1 × 360◦ (89 CP) 151 201
5 Larynx 61/50 5 fields (23 CP) 1 × 260◦ (77 CP) 182 109
Lung 6 Lt. lung 60 5 fields (17 CP) 1 × 230◦ (73 CP) 167 64
7 Lt. lung 60 2 × 225◦ (116 CP) 1 × 225◦ (63 CP) 94 67
8 Rt. lung 60 6 fields (21 CP) 1 × 192◦ (61 CP) 237 126
9 Rt. lung 60 2 × 210◦ (108 CP) 1 × 210◦ (63 CP) 90 98
10 Lt. lung and
mediastinum
50 2 × 360◦ (181 CP) 1 × 360◦ (93 CP) 149 100
Prostate 11 Prostate 76 1 × 360◦ (91 CP) 1 × 360◦ (99 CP) 79 129
12 Prostate bed 66 2 × 360◦ (182 CP) 1 × 360◦ (97 CP) 151 200
13 Prostate 45 2 × 360◦ (182 CP) 1 × 360◦ (103 CP) 150 236
14 Prostate bed 76/50.4 2 × 360◦ (182 CP) 1 × 360◦ (93 CP) 154 241
15 Prostate 66 2 × 360◦ (182 CP) 1 × 360◦ (96 CP) 151 139
Note: pres, prescription; Rt, right; Lt, left; UIMAT, unified intensity modulated arc therapy; CP, control points.
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cases, mean doses for parotids, oral cavity, and larynx, and
maximum doses for cord, brainstem, and larynx were ana-
lyzed. For lung cases, mean doses for lung, esophagus, and
heart were recorded as well as the lung V20 and the maximum
cord dose. For prostate cases, mean doses for rectum, bladder,
bowel, and femurs were analyzed. The threshold for statistical
significance was set at a p-value of 0.05.
The deliverability of UIMAT plans was tested on a Varian
TrueBeam linear accelerator (Varian Medical Systems, Palo
Alto). The accuracy of dose calculations and delivery was
verified by measurements with the ArcCheck Phantom (Sun
Nuclear).
3. RESULTS
3.A. Feasibility
The UIMAT plans were generated for 15 cases, as sum-
marized in Table I. UIMAT plans employed only one arc,
while most of the clinical VMAT plans required two arcs.
The number of MLC control points in the UIMAT plans
was less than the VMAT plans for all but one case (see
Table I), but more than in the IMRT plans. The estimated
delivery times for UIMAT plans were not significantly
different from the VMAT plans (p = 0.22) but they were
significantly faster than multiple-field IMRT plans (p= 0.01).
No significant difference in delivery time was observed
between the UIMAT plans and the VMAT and IMRT plans
taken together (p= 0.75).
An ArcCheck measurement in each treatment site was
made to verify the accuracy of UIMAT dose calculation and
feasibility of delivery. All tested plans had a gamma passing
rate16 of greater than 95% using our standard clinical param-
eters of 3% dose difference and 3 mm distance-to-agreement.
3.B. Plan comparison
3.B.1. Head and neck
The dose metrics used in the evaluation of the head-
and-neck cases are presented in Table II. Plans which have
multiple PTVs, as listed in Table I, have one CI reported
for each PTV. For patient 5, the low doses associated with
most organs at risk (OARs) are related to the small treatment
volume which is restricted to the laryngeal region of the
neck. For the five head-and-neck cases, the overall average
of the mean OAR doses in Table II was reduced by 8.4%
(p < 0.001) using UIMAT plans compared to the clinical
VMAT or IMRT plans. As a specific example, comparison
of the dose distributions and DVHs between a UIMAT and
a VMAT plan for a head-and-neck case is shown in Fig. 3.
It shows that the UIMAT plan produced lower OAR doses
with similar PTV coverage compared with the clinical VMAT
plan.
3.B.2. Lung
The dose metrics used in the evaluation of the lung cases are
presented in Table III. UIMAT yielded significant reductions
for the mean doses for heart and esophagus, and maximum
cord dose compared with clinical IMRT or VMAT plans,
while the difference in V20, mean lung dose, conformity
index, and mean PTV dose is not statistically significant. The
overall average of the mean OAR doses in Table III was
reduced by 5.7% (p < 0.001) using UIMAT plans compared
with clinical IMRT or VMAT plans.
As a specific example, comparison of the dose distributions
and DVHs between a UIMAT and a five-field IMRT plan for
a lung case is shown in Fig. 4. The UIMAT plan produced
more conformal and uniform dose to the PTV and lower doses
T II. Dose volume parameters of interest for five head-and-neck cases. The mean PTV dose is represented as a percentage of the prescription dose. Certain
OARs were not contoured for some patients, either because the OAR was well outside the treatment volume or because it was completely enclosed within the
PTV. The conformity indices correspond to the target volumes listed in the third-last column, and similarly for the mean PTV doses. Since not all patients had
the same number of PTV dose levels, P values and average doses for PTVs were calculated for the highest dose level only.
No. Plan
Oral
cavity
D¯ (Gy)
Left
parotid
D¯ (Gy)
Right
parotid
D¯ (Gy)
Larynx
D¯ (Gy)
Larynx
Dmax
(Gy)
Brainstem
Dmax
(Gy)
Cord
Dmax
(Gy)
PTV(s)
Pres. (Gy)
Conformity
index PTV(s) D¯ (%)
1
Clinical 28.4 6.9 — 31.8 62.3 15.0 22.4
64/60/54
0.21/0.77/0.63 99.8/101.5/103.5
UIMAT 22.6 2.4 — 26.8 61.2 9.5 24.5 0.14/0.79/0.63 101.9/102.6/103.7
2
Clinical 30.0 5.9 61.0 27.8 62.6 13.8 36.7
60
0.85 101.3
UIMAT 27.7 3.3 60.8 26.3 63.1 10.9 37.4 0.80 101.5
3
Clinical 33.2 25.9 25.6 — — 32.2 36.9
70/56
0.83/0.79 100.0/101.8
UIMAT 29.9 23.1 22.4 — — 33.3 44.3 0.70/0.70 101.7/102.6
4
Clinical 39.3 25.3 25.4 48.6 65.1 44.3 44.8
70/56
0.78/0.72 100.6/104.5
UIMAT 37.3 22.5 22.9 47.7 58.0 46.0 23.4 0.82/0.71 100.7/103.6
5
Clinical 0.2 0.2 0.2 55.5 64.2 0.2 0.2
61/50
0.89/0.73 101.0/109.6
UIMAT 0.2 0.2 0.2 55.5 64.0 39.8 23.6 0.93/0.73 101.6/108.6
Avg.
Clinical 26.2 12.8 28.0 40.9 63.6 21.1 31.8 0.72 102.4
UIMAT 23.6 10.3 26.6 39.0 61.6 20.0 34.9 0.7 102.9
P value 0.02 0.01 0.09 0.09 0.17 0.23 0.04 0.11 0.08
Note: PTV, planning target volume; OAR, organ at risk; UIMAT, unified intensity modulated arc therapy; D¯, mean dose; Dmax, maximum dose; avg, average.
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F. 3. Comparison of dose distributions between a clinical VMAT plan (top left) and a UIMAT plan (top right) and corresponding dose volume histograms
(bottom) for a head-and-neck case (patient 1).
to left lung, esophagus, and spinal cord compared with the
IMRT plan.
3.B.3. Prostate
The dosimetric parameters of UIMAT and clinical VMAT
plans for five prostate cases are shown in Table IV. The
multiple conformity indices for patient 14 correspond to the
multiple PTVs within the plan. No significant dosimetric
difference was observed between UIMAT and VMAT plans
for the prostate cases studied. The overall average of the
mean OAR doses listed in Table IV was reduced by 3.5%
(p= 0.009) using UIMAT compared with VMAT plans. As
a specific example, comparison of the dose distributions and
T III. Dose volume parameters of interest for five lung cases. The mean PTV dose is represented as a percentage of the prescription dose.
No. Plan
Lung V20
(%)
Lung D¯
(Gy)
Esophagus
D¯ (Gy)
Heart D¯
(Gy)
Cord Dmax
(Gy) CI PTV D¯ (%)
6
Clinical 15.1 9.8 17.1 1.2 29.5 0.72 101.7
UIMAT 14.9 9.2 15.7 1.0 27.9 0.87 102.0
7
Clinical 21.9 14.0 22.4 10.1 35.6 0.87 101.3
UIMAT 22.1 14.0 21.2 8.3 34.8 0.91 101.3
8
Clinical 30.5 17.2 25.0 11.0 47.8 0.79 103.5
UIMAT 27.8 15.5 22.7 10.6 47.4 0.91 101.5
9
Clinical 20.7 11.8 24.4 4.8 43.3 0.78 101.3
UIMAT 20.7 11.5 23.3 3.8 41.2 0.81 101.3
10
Clinical 35.6 18.6 36.2 30.6 43.4 0.92 100.2
UIMAT 34.4 18.1 35.5 29.4 42.5 0.88 101.0
Avg.
Clinical 24.8 14.3 25.0 11.5 39.9 0.82 101.6
UIMAT 24.0 13.7 23.7 10.6 38.8 0.88 101.4
P value 0.12 0.05 0.003 0.01 0.01 0.08 0.37
Note: PTV, planning target volume; CI, conformity index; V20, percent volume of lung receiving at least 20 Gy; D¯, mean dose; Dmax, maximum dose; UIMAT, unified
intensity modulated arc therapy; avg, average.
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F. 4. Comparison of dose distributions between a clinical IMRT plan (top left) and a UIMAT plan (top right) and corresponding dose volume histograms
(bottom) for a lung case (patient 6).
DVHs between a UIMAT and a VMAT plan for a prostate
case is shown in Fig. 5. In this case, the UIMAT plan is
dosimetrically similar to the clinical VMAT plan.
4. DISCUSSION
We have shown that it is feasible to optimize and deliver
UIMAT which combines VMAT and IMRT within the same
arc. We have also shown how the degree of intensity mo-
dulation can be naturally incorporated into an algorithm
which dynamically varies the angular density of the beam
control points. Compared with clinical VMAT or IMRT
plans, UIMAT has the potential to produce efficient and
superior radiation dose distributions, especially for complex
anatomy such as in head-and-neck cancers. On the other hand,
for the sites with more rotational symmetry, such as prostate,
UIMAT may not yield significant advantages as it resulted
T IV. Dose–volume parameters of interest for five prostate cases. The bowel was not contoured for two patients as it lay well outside the treatment volume.
The conformity indices correspond to the target volumes listed in the third-last column, and similarly for the mean PTV doses. Since not all patients had the
same number of PTV dose levels, P values for PTVs were calculated for the highest dose level only.
No. Plan
Rectum
D¯ (Gy)
Bladder
D¯ (Gy)
Bowel D¯
(Gy)
Lt. femur D¯
(Gy)
Rt. femur D¯
(Gy)
PTV(s) pres.
(Gy)
Conformity
index PTV D¯ (%)
11
Clinical 41.4 15.0 — 19.0 22.6
76
0.83 101.4
UIMAT 39.2 12.3 — 16.3 17.6 0.85 101.9
12
Clinical 41.4 54.3 53.1 22.4 16.5
66
0.82 98.2
UIMAT 42.8 55.5 52.2 20.8 20.8 0.87 98.1
13
Clinical 34.2 34.2 28.8 16.1 15.3
45
0.78 103.4
UIMAT 32.2 33.4 26.3 16.2 13.8 0.84 101.9
14
Clinical 45.6 45.5 31.6 22.9 21.5
76/50.4
0.91/.0.60 102.0/107.0
UIMAT 46.4 43.8 29.7 19.4 21.6 0.88/0.59 102.2/106.6
15
Clinical 32.3 17.9 — 23.4 23.3
66
0.91 100.9
UIMAT 32.1 17.8 — 21.7 22.5 0.84 100.9
Average
Clinical 39.0 33.4 37.85 20.8 19.8 0.81 102.1
UIMAT 38.6 32.6 36.1 18.9 19.3 0.81 101.9
P value 0.29 0.16 0.03 0.02 0.37 0.39 0.26
Note: PTV, planning target volume; Lt, left; Rt, right; pres, prescription; D¯, mean dose; UIMAT, unified intensity modulated arc therapy.
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F. 5. Comparison of dose distributions between a clinical VMAT plan (top left) and a UIMAT plan (top right) and corresponding dose volume histograms
(bottom) for a prostate case (patient 14).
in plans with comparable dosimetric performance but less
efficient delivery compared with VMAT.
One of the virtues of our proposal is that the switch
from the current VMAT technique to our unified approach
would, in principle, be seamless. Treatment planning for
UIMAT would be the same as for VMAT as no selection
of static beam directions is required. Similarly, radiation
therapists delivering the treatment would not need to perform
any additional steps beyond what is commonly done for
stand-alone VMAT delivery, although they must be made
aware of the stopped gantry during IMRT phases of UIMAT
delivery. Another benefit of our proposal is the ease at which
it can be incorporated into a working clinical system, thus
decreasing both cost and time between conception and clinical
implementation. Of course, in practice, the introduction of
this technique, as with all new techniques, would require
additional quality assurance and testing.
Compared with other IMRT/VMAT combination tech-
niques,7–12 our proposal offers simplicity in integration,
optimization, and delivery. Our UIMAT proposal is not simply
an IMRT/VMAT hybrid technique. It would be more correct to
refer to it as a more fully realized implementation of VMAT
with fuller range of gantry speed that even permits gantry
stalls, thus allowing for optimal beam modulation. What we
have demonstrated is one specific implementation of UIMAT,
and in principle, it could be generalized further. UIMAT could
be further developed with more robust segmentation and
optimization algorithms, as well as more degrees of freedom
such as collimator angle, couch position, and couch angle.
Such future developments could hopefully address certain
limitations within our initial implementation of UIMAT. For
example, once the initial gantry directions are chosen for
IMRT phases at the start of optimization, they cannot be
altered at a later point in the optimization. For most cases,
this should not be a problem, except if the objective function
changes dramatically between initial and final optimization.
It should be noted that the same is true for VMAT and IMRT
planning. After the fluence map conversion takes place, it
becomes much easier for the optimization routine to become
trapped in local minima.
In the planning comparison portion of this work, we
acknowledge the usual biases and confounders inherent in
such an approach. For example, there is a natural tendency
toward demonstrating that a new treatment is superior to
the standard-of-care. More effort may be spent optimizing
the new technique or choosing comparison endpoints that
naturally favor the new method. Unfortunately, requiring the
matching of equal planning effort is not practical, but we were
conscious in avoiding “overoptimizing” the UIMAT plans. In
this retrospective study, the actual difference in planning time
was not logged precisely. Depending on the complexity of
the case, clinical planning in our experience requires 1–4 h.
To ensure a fair planning comparison, we restricted UIMAT
planning times to fall within a similar range.
We acknowledge that the number of cases tested in this
feasibility study is very limited and so the statistics reported
only highlight general trends. More cases are needed for each
treatment site to confirm the conclusions reached. Finally, as
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mentioned earlier, dynamic jaws are needed when treating
large volumes with a single arc due to the finite speed and
length of the MLC leaves. This is an obvious advantage for
UIMAT as it allows more freedom for collimating the beam;
however comparable degrees of freedom were still available
in our clinical plans but required more than one arc with
differing jaw positions.
Compared to other published techniques7–12 combining
IMRT and VMAT, UIMAT is unique in that it possesses all
of the following features: (1) it creates VMAT and IMRT
phases automatically; (2) it optimizes VMAT and IMRT
phases simultaneously; (3) the VMAT and IMRT phases are
combined and delivered in a single dynamic arc; (4) the
algorithm has been implemented on a commercial treatment
planning system; (5) the UIMAT plans have been validated
using the ArcCheck phantom, delivered in clinical mode on
a Varian TrueBeam linear accelerator. Theoretically, it is
known that the increased degrees of freedom afforded by
the IMRT phases of the arc will, in principle, lead to a
superior plan, all other things being equal. What we have
shown is that this appears to be the case, even with this
simple initial implementation. Further improvements in the
optimization beyond what is possible within a commercial
treatment planning software should lead to even better results.
Last but not least, our work shows that the UIMAT delivery
speed is improved over IMRT or when multiple VMAT arcs
are required.
5. CONCLUSIONS
We have demonstrated the feasibility of a novel radiation
therapy delivery technique termed UIMAT. This technique
combines VMAT and IMRT optimization concurrently and
delivers radiation in a single arc. The optimal fixed-
gantry IMRT phases are chosen automatically during the
optimization. Optimization of both the VMAT and fixed-
gantry IMRT phases of delivery occurs simultaneously, and
the final plan is an integrated UIMAT plan. Initial results
show that the UIMAT has the potential to be superior to either
stand-alone IMRT or VMAT in terms of dose distribution
quality and efficiency of delivery.
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